10.52
-2.05%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Boai NKY Medical Holdings
Its shares trade on Shenzhen under the ticker 300109.SZ. It has been listed since 25 August 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.18bn and net income of CN¥190.1m. At that date it held total assets of CN¥4.37bn and shareholders' equity of CN¥3.68bn.
Boai NKY Medical Holdings Ltd. engages in the operation of pharmaceutical excipients, polyvinylpyrrolidone series products and vinyl methyl ether and maleic anhydride polymer products. The company is headquartered in Jiaozuo, Henan. The company went IPO on 2010-08-25. The Company’s main products include GBL, 2- pyrrolidone, N-vinylpyrrolidone (NVP) monomer, PVP-K series (PVPK), polyvinylpolypyrrolidone (PPVP), PVP- Iodine (PVP-I), related pharmaceutical intermediates and others. The firm's products are mainly used in daily chemical, medicine, liquor and beverage, pigments and coatings, textile, paper making, oil extraction, sensitive material, electronic and other industries. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 25 Aug 2010
- Employees
- 1,047
- Website
- nkygroup.cn ↗
Leadership
Pay as last reported
- Mr. Junzheng ZhangChairman of the Board, General Manager, since 2009CN¥64,100
- Mr. Hongbo YangVice Chairman of the Board, since 2019CN¥65,300
- Mr. Wei ZhaoVice Chairman of the Board
- Mr. Aimin LiuChief Financial OfficerCN¥60,900
- Mr. Xiaoliang XingDeputy General Manager, Secretary of the Board
- Ms. Yunxia QuSenior Deputy General Manager, Director, since 2009CN¥148,200
- Mr. Jiangtao YuSenior Deputy General Manager, Director, since 2023
- Xianghua DingDeputy General ManagerCN¥189,000
- Mr. Shegang LiDeputy General Manager
- Ms. Dan LiuDeputy General Manager, since 2019
- Mr. Haizhan MaoDeputy General Manager
- Mr. Dalong RenDeputy General Manager
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates in pharmaceutical excipients and chemical products with a focus on PVP series and polymer products.
- Has a domestic and international market presence for its chemical products.
- Employs 1,047 full-time employees, indicating a stable workforce.
Weaknesses
- Relies on a narrow product range including GBL, 2-pyrrolidone, and NVP monomer.
- Operates in the Materials sector under Chemicals, which may face regulatory challenges.
- No specific information provided about financial performance or market share.
Opportunities
- Expanding into new industries such as electronics and sensitive materials for product diversification.
- Growing demand for pharmaceutical intermediates in the global market.
- Potential for increased international distribution to overseas markets.
Threats
- Regulatory challenges in the chemical industry could impact operations.
- Competition from other chemical manufacturers in domestic and international markets.
- Dependence on specific product lines may limit adaptability to market changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.